PPP2CB Antibody

What is PPP2CB and how does it function in cellular processes?

PPP2CB, also known as Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform or PP2A-beta, is one of two catalytic subunit isoforms of protein phosphatase 2A (PP2A), a major serine/threonine phosphatase in eukaryotic cells. PP2A functions as a heterotrimeric holoenzyme consisting of:

• A scaffolding A subunit (PR65A or PR65B)

• A catalytic C subunit (PPP2CA or PPP2CB)

• A regulatory B subunit (from multiple families including B55, B56, PR72, and PR93/PR110)

PPP2CB plays a crucial role in the catalytic activity of PP2A complexes, which modulate numerous cellular processes by dephosphorylating various substrates. PP2A can regulate the activity of several enzymes including phosphorylase B kinase, casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase .

As part of striatin-interacting phosphatase and kinase (STRIPAK) complexes, PPP2CB participates in regulating multiple signaling pathways including Hippo, MAPK, nuclear receptor and cytoskeleton remodeling pathways. These interactions contribute to various biological processes such as cell growth, differentiation, apoptosis, metabolism, and immune regulation .

PP2A also functions as a tumor suppressor by constraining phosphorylation-dependent signaling pathways that regulate cellular transformation and metastasis, making it a potential therapeutic target in cancer research .

What are the key differences between PPP2CA and PPP2CB isoforms, and how do these differences affect antibody selection?

Despite their functional similarities, PPP2CA and PPP2CB have several important differences that researchers should consider when selecting antibodies:

Structural and Expression Differences:

• PPP2CA and PPP2CB share 97% amino acid sequence homology, with variations primarily occurring at the N-terminus

• PPP2CA is typically over 10-fold more abundant than PPP2CB in most cells due to stronger promoter activity and differences in mRNA turnover rates

• The two isoforms may have non-redundant functions, as null mutation of PPP2CA can be lethal, suggesting distinct biological roles

Antibody Selection Considerations:

Many commercially available antibodies recognize both isoforms due to their high sequence similarity. As noted in one study: "as far as we were aware, no antibody specifically detecting PPP2CA or PPP2CB is commercially available" . This cross-reactivity presents significant challenges for isoform-specific research.

To address this issue, researchers should:

• Examine the immunogen information provided by manufacturers to determine if the antibody targets a region of difference between isoforms

• Validate specificity through molecular approaches such as:

  • siRNA knockdown of each isoform separately (example sequence from research: Sense: 5′-AGAGGCGAGCCACAUGUUATT-3′)

  • CRISPR/Cas9 knockout of specific isoforms

  • Overexpression of tagged versions of each isoform

• Consider using genetic tagging approaches as demonstrated in recent research where CRISPR/Cas9 was used to create dTAG/dTAG PPP2CA knock-in HEK293 cells, enabling clear discrimination between tagged PPP2CA (48 kDa) and untagged PPP2CB (35 kDa)

When absolute isoform specificity is required, verification using multiple complementary approaches is strongly recommended to ensure reliable experimental outcomes.

What applications can PPP2CB antibodies be used for, and what are the recommended protocols?

PPP2CB antibodies can be utilized across multiple experimental applications, each requiring specific optimization parameters:

Western Blotting (WB):

• Recommended dilutions: 1:500-1:2000

• Expected molecular weight: 36 kDa (primary band)

  • Note: Additional bands at 190 kDa and 28 kDa have been observed in some systems

• Protocol highlights:

  • Protein loading: 5-50 μg depending on expression level

  • Examples from validation: HeLa, 293T, NIH3T3, and PANC-1 cell lysates

  • Typical exposure time: 3 minutes for standard detection

Immunoprecipitation (IP):

• Recommended amounts: 0.5-4.0 μg antibody per 1.0-3.0 mg total protein lysate

• Alternative recommendation: 1:100 dilution for IP applications

• Protocol considerations:

  • Buffer example: 20 mM Imidazole-HCl, 2mM EGTA, 2mM EDTA, pH7.0, with protease inhibitors

  • Include appropriate controls (non-specific IgG)

Immunohistochemistry (IHC):

• Recommended dilutions: 1:100-1:1000

• Validated tissues: rat kidney tissue, human stomach cancer tissue

• Antigen retrieval: TE buffer pH 9.0 or citrate buffer pH 6.0

Immunocytochemistry (ICC):

• Recommended dilutions: 1:50-1:200

• Validated in: PANC-1 cells with nuclear counterstain (DAPI)

Phosphatase Activity Assay:

For functional studies, PPP2CB can be immunoprecipitated and assayed for phosphatase activity:

• Immunoprecipitate PPP2CB from cell extracts

• Incubate with phosphopeptide substrate

• Measure free phosphate using malachite green phosphate detection

• Measure absorbance at 620 nm

• Include okadaic acid (1-10 nM) as a specific inhibitor control

How can I validate the specificity of PPP2CB antibodies for my experimental system?

Given the high sequence homology between PPP2CA and PPP2CB, thorough validation is essential. A comprehensive approach includes:

Genetic Validation Methods:

• Knockdown/Knockout Approaches:

  • siRNA-mediated knockdown targeting PPP2CB specifically

  • Example sequence: Sense: 5′-AGAGGCGAGCCACAUGUUATT-3′; Antisense: 3′-TTUCUCCGCUCGGUGUACAAU-5′

  • CRISPR/Cas9-engineered knockout cell lines (as demonstrated with PPP2CA in dTAG/dTAG PPP2CA knock-in HEK293 cells)

  • Compare antibody signal between control and knockdown/knockout samples

• Overexpression Systems:

  • Express tagged versions of PPP2CB (e.g., HA-tagged) as positive controls

  • Compare detection between endogenous and overexpressed protein

Biochemical Validation Methods:

• Western Blot Analysis:

  • Verify correct molecular weight (36 kDa expected for PPP2CB)

  • Example from published data: "Predicted band size: 36 kDa; Observed band size: 190 kDa, 28 kDa, 36 kDa"

  • Compare patterns between antibodies targeting different epitopes

• Peptide Competition Assay:

  • Pre-incubate antibody with immunizing peptide

  • Should eliminate specific signal in Western blot or immunostaining

• Cross-reactivity Assessment:

  • Test reactivity with PPP2CA to determine potential cross-reactivity

  • Examine reactivity across multiple species if cross-species reactivity is claimed

Functional Validation:

• Immunoprecipitation and Mass Spectrometry:

  • Identify pulled-down proteins to confirm PPP2CB specificity

  • Look for associated PP2A complex proteins (A and B subunits)

• Phosphatase Activity Assays:

  • Immunoprecipitate PPP2CB and measure phosphatase activity

  • Include okadaic acid (1-10 nM) as a specific inhibitor control

  • Measure activity using malachite green:phosphate complex absorbance at 620 nm

Comprehensive validation using multiple approaches provides the strongest evidence for antibody specificity, particularly when studying proteins with high homology to other family members.

What controls should be included when using PPP2CB antibodies in different applications?

Proper controls are essential for interpreting results obtained with PPP2CB antibodies. Here are the key controls for different applications:

Western Blotting Controls:

• Positive Controls:

  • Cell lines with known PPP2CB expression (e.g., HeLa, 293T, NIH3T3)

  • Recombinant PPP2CB protein

  • Overexpression system with tagged PPP2CB

• Negative Controls:

  • siRNA/shRNA knockdown of PPP2CB

  • CRISPR/Cas9 knockout cells if available

  • Secondary antibody-only control

• Specificity Controls:

  • Competition with immunizing peptide

  • Loading control (e.g., GAPDH, as used in published studies)

Immunoprecipitation Controls:

• Input Control:

  • 5-10% of total lysate used for IP

  • Essential for comparing relative enrichment

• Negative Control Immunoprecipitation:

  • Non-specific IgG from same species as primary antibody

  • Example from published data: "Lane 1: ab72343 at 3μg/mg whole cell lysate. Lane 2: Control IgG."

• Validation Control:

  • Western blot of IP product with same antibody

  • Western blot with antibody against known interaction partners

Immunohistochemistry/Immunocytochemistry Controls:

• Positive Controls:

  • Tissues with known PPP2CB expression (e.g., rat kidney)

  • Cells with confirmed expression (e.g., PANC-1 cells)

• Negative Controls:

  • Primary antibody omission

  • Isotype control antibody

  • Pre-immune serum (for polyclonal antibodies)

  • Peptide-blocked antibody

• Specificity Controls:

  • siRNA-treated cells

  • Tissues from knockout animals (if available)

Phosphatase Activity Assay Controls:

• Enzyme Controls:

  • Recombinant PPP2CB as positive control

  • Heat-inactivated sample as negative control

• Inhibitor Controls:

  • Okadaic acid at 1 nM and 10 nM concentrations

  • Example from research: "To further verify specificity of PPP2CA activity, additional immunoprecipates were run in the presence of okadaic acid (OA, a widely used PPP2CA inhibitor; Ki = 0.2 nM) at 1 or 10 nM"

• Reaction Controls:

  • No substrate control

  • No enzyme control

Systematic inclusion of these controls ensures reliable interpretation of experimental results and helps distinguish specific signals from background or artifacts.

How do post-translational modifications of PPP2CB affect antibody detection?

Post-translational modifications (PTMs) of PPP2CB can significantly impact antibody recognition and lead to misinterpretation of experimental results:

Common PTMs Affecting PPP2CB Recognition:

• Phosphorylation:

  • PPP2CB can be phosphorylated at various sites

  • Phosphorylation can alter protein conformation and epitope accessibility

  • May result in mobility shifts on SDS-PAGE gels

  • Can affect binding of antibodies that recognize regions containing phosphorylation sites

• Methylation:

  • C-terminal leucine (Leu309) methylation affects PPP2CB function

  • This modification can alter antibody binding to C-terminal epitopes

  • May be particularly relevant for antibodies targeting the C-terminus

• Ubiquitination:

  • Targets PPP2CB for degradation

  • Can cause appearance of higher molecular weight bands or smears

  • May mask epitopes recognized by some antibodies

Impact on Experimental Applications:

Methodological Recommendations:

• Sample Preparation:

  • Use fresh samples when possible

  • Include comprehensive protease and phosphatase inhibitor cocktails

  • Consider native vs. denaturing conditions based on antibody specifications

  • For phosphorylation studies, compare samples with and without phosphatase inhibitors

• Antibody Selection:

  • Know your antibody's epitope location relative to known PTM sites

  • Consider using multiple antibodies targeting different regions

  • Consult available literature about the specific antibody's sensitivity to PTMs

• Complementary Approaches:

  • Use mass spectrometry to identify specific PTMs on PPP2CB

  • Employ Phos-tag gels to separate phosphorylated from non-phosphorylated forms

  • Compare results across multiple detection methods

Understanding the relationship between PTMs and antibody recognition is crucial for accurate interpretation of PPP2CB detection results, particularly in studies examining regulatory mechanisms affecting PP2A function.

What are the challenges and solutions for detecting PPP2CB in different subcellular compartments?

PP2A enzymes, including PPP2CB-containing complexes, can localize to various subcellular compartments depending on their regulatory subunits and cellular context. This presents specific challenges for accurate detection:

Challenges in Subcellular Detection:

• Differential Expression Levels:

  • PPP2CB concentration varies across subcellular compartments

  • Nuclear pools may be less abundant than cytoplasmic pools

  • Membrane-associated fractions may require specific extraction methods

• Complex Association Variations:

  • Different B regulatory subunits direct PP2A to specific locations

  • As noted in research: "B56 subunits can also act as receptors of second messengers... B56 subunits are phosphoproteins"

  • These associations may mask antibody epitopes in compartment-specific ways

• Fixation and Permeabilization Effects:

  • Different fixatives may affect epitope accessibility differently across compartments

  • Membrane structures may require specific permeabilization conditions

For Immunofluorescence/Immunocytochemistry:

• Optimized Fixation Protocols:

  • Compare multiple fixatives (4% PFA, methanol, acetone)

  • Adjust fixation times based on compartment of interest

  • Consider epitope retrieval methods

• Permeabilization Optimization:

  • Test different detergents (Triton X-100, saponin, digitonin)

  • Adjust concentrations based on target compartment

  • Example from research: ICC staining of PPP2CB in PANC-1 cells shows both nuclear and cytoplasmic distribution

• Co-localization Studies:

  • Use established compartment markers

  • Nuclear: DAPI, Hoechst

  • ER: calnexin, PDI

  • Golgi: GM130

  • Confirm localization with confocal microscopy

For Biochemical Fractionation:

• Fraction-Specific Extraction Protocols:

  • Nuclear extraction: use specialized nuclear extraction buffers

  • Membrane fractions: include detergents appropriate for membrane solubilization

  • Cytoskeletal fraction: special considerations for insoluble components

• Marker Validation:

  • Confirm fractionation quality with compartment-specific markers

  • Nuclear: Lamin B, Histone H3

  • Cytoplasmic: GAPDH, tubulin

  • Membrane: Na+/K+ ATPase, calnexin

• Extraction Buffer Considerations:

  • Include phosphatase inhibitors to preserve phosphorylation states

  • Adjust salt concentration based on target compartment

  • Consider non-ionic detergents for membrane fractions

Advanced Techniques:

• Proximity Ligation Assay (PLA):

  • Detect PPP2CB interactions in specific compartments

  • Higher specificity than conventional immunofluorescence

  • Can detect specific interaction partners in defined subcellular regions

• FRET/BRET Approaches:

  • For live cell studies of PPP2CB localization

  • Requires tagged PPP2CB constructs

  • Allows real-time monitoring of translocation events

By addressing these challenges with appropriate methodological solutions, researchers can accurately detect and study the compartment-specific roles of PPP2CB in various cellular processes.

How can PPP2CB antibodies be used to study the role of PP2A in neurodegeneration and other disease models?

PP2A plays critical roles in neurodegeneration and various disease processes, making PPP2CB antibodies valuable tools for mechanistic and therapeutic studies:

PP2A in Neurodegeneration:

PP2A is particularly important in neurodegenerative conditions, with research showing:

• "PPP2R5D is abundantly expressed in the brain and involved in a broad range of cellular processes"

• PP2A dysregulation is implicated in Alzheimer's disease, where it normally regulates tau phosphorylation

• "PP2A constrains inflammatory responses through its inhibitory effects on various signalling pathways" , which is relevant to neuroinflammatory conditions

• "PP2A-activating drugs (PADs) are being actively sought... as potential novel anti-cancer treatments" , with potential applications in neurodegeneration

Tissue-Specific Analysis:

• Brain Section Immunohistochemistry:

  • Recommended dilution: 1:250-1:1000

  • Antigen retrieval: "TE buffer pH 9.0 or citrate buffer pH 6.0"

  • Compare affected vs. unaffected brain regions

  • Include age-matched controls

  • Co-stain with neuron/glia markers and disease-specific markers (tau, Aβ, α-synuclein)

• Primary Neuron Cultures:

  • ICC applications: 1:50-1:200 dilution

  • Study subcellular localization in neuronal compartments

  • Evaluate changes upon disease-relevant stressors

  • Monitor colocalization with disease proteins

• Biochemical Analysis:

  • Western blotting of brain tissue/neuronal lysates

  • IP/Co-IP to identify disease-specific interaction partners

  • Phosphatase activity assays of immunoprecipitated PPP2CB

Disease Model Applications:

Translational Research Applications:

• Therapeutic Response Monitoring:

  • Track PP2A activity/localization changes in response to experimental therapeutics

  • Use PPP2CB antibodies for analyzing patient samples before/after treatment

  • Correlate PP2A complex formation with disease progression

• Biomarker Development:

  • Analyze PPP2CB expression/modification patterns in accessible patient samples

  • Correlate with disease severity or progression

  • Combine with functional readouts of PP2A activity

• Drug Development Support:

  • Screen compounds for effects on PPP2CB localization/activity

  • Evaluate PP2A complex formation in response to therapeutic candidates

  • Monitor restoration of normal PP2A function

By employing these approaches with well-validated PPP2CB antibodies, researchers can gain valuable insights into the role of PP2A in neurodegeneration and other disease processes, potentially leading to new therapeutic strategies targeting this important phosphatase system.